Market Research Report
North America Botulinum Toxin Market Forecast 2021-2028
|Published by||Inkwood Research||Product code||1003286|
|Published||Content info||123 Pages
Delivery time: 2-3 business days
|North America Botulinum Toxin Market Forecast 2021-2028|
|Published: May 11, 2021||Content info: 123 Pages||
The North America botulinum toxin market is forecasted to progress with a CAGR of 4.77% over the estimated period of 2021 to 2028. The region's market growth is facilitated by factors like the presence of combination therapies for facial rejuvenation products and the upsurge in the geriatric populace.
The North America botulinum toxin market growth analysis entails the assessment of Canada and the United States. Canada comprises several domestic and global players, intensely competing among themselves. While the majority of the population across eastern countries retire by the age of 60, the retirement age in Canada is 65, resulting in an additional five years of professional and social life. This aspect creates the need to appear energetic and young, thereby bolstering the demand for cosmetic procedures. As per the Government of Canada, the country's citizens choose non-invasive aesthetic treatments in order to minimize facial wrinkles and improve their appearances. Besides,
On the other hand, botulinum neurotoxin injections are used for both cosmetic and medical purposes. The three forms of botulinum toxins available for patients in Canada include botulinum toxin type A, with trade names Botox, Xeomin, and Dysport). According to the International Society of Aesthetic Plastic Surgery (ISAPS) 2018 Report, the country has 530 plastic surgeons contributing to the botulinum toxin market. Moreover, Daewoong Pharmaceutical's exclusive sales partner, Evolus, acquired the marketing approval of Nuceiva (botulinum toxin) in August 2018 from Health Canada. Hence, these factors are set to facilitate the market growth in Canada over the forecasting years.
Some of the key companies operating in the market are Medytox, Ipsen Pharma, Allergan PLC, etc.